Alnylam (ALNY) Q3 FY25 earnings call

Alnylam reported a robust Q3 FY25, driven by exceptional commercial performance of its TTR franchise, particularly the AMVUTTRA ATTR-CM launch in the U.S. The company significantly raised its full-year net product revenue guidance, underscoring confidence in its commercial strategy. Alongside strong financial results, Alnylam advanced its pipeline with two new Phase III trials and several earlier-stage programs, aiming for sustainable innovation and long-term value creation.